. Author manuscript; available in PMC: 2021 Jul 28.

Published in final edited form as: Mov Disord. 2020 May 1;35(8):1388–1395. doi: 10.1002/mds.28060

TABLE 1.

Demographics and clinical data

	PD	MSAp	PSP
Sample size	38	17	16
Age, y	64.84 (9.03)	67.71 (9.12)	70.94 (7.77)
Sex, male/female	29/9	12/5	7/9
Disease duration, mos.	48.13 (29.44)	55.47 (35.39)	35.94 (32.14)
Total LEDD	693.32 (259.09)^b,c	448.82 (570.93)^a	429.69 (364.83)^a
Hoehn & Yahr stage	1.92 (0.49)^b,c	3.35 (1.00)^a,c	3.06 (1.18)^a,b
MDS-UPDRS III	28.13 (11.88)^b,c	44.53 (14.45)^a	41.81 (13.87)^a
MoCA	25.50 (2.87)^b,c	21.18 (4.73)^a	21.19 (5.38)^a
NfL	13.30 (6.29)^b,c	27.08 (17.81)^a	26.05 (14.88)^a
MRPI	10.66 (2.60)^c	10.85 (4.90)^c	18.77 (7.01)^a,b

Abbreviations: PD, Parkinson’s disease; MSAp, multiple system atrophy parkinsonian variant; PSP, progressive supranuclear palsy; LEDD, levodopa equivalent daily dose; MDS-UPDRS III, Part III of the Movement Disorders Society Unified Parkinson’s Disease Rating Scale; MoCA, Montreal Cognitive Assessment; NfL, neurofilament light chain protein; MRPI, Magnetic Resonance Parkinsonism Index.

P < 0.05 versus PD.

P < 0.05 versus MSAp.

P < 0.05 versus PSP.